Evelo Biosciences Performance
| EVLODelisted Stock | USD 8.23 2.68 24.56% |
The firm shows a Beta (market volatility) of -2.75, which means a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Evelo Biosciences are expected to decrease by larger amounts. On the other hand, during market turmoil, Evelo Biosciences is expected to outperform it. Evelo Biosciences right now shows a risk of 0.0%. Please confirm Evelo Biosciences value at risk, and the relationship between the jensen alpha and skewness , to decide if Evelo Biosciences will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Evelo Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy essential indicators, Evelo Biosciences is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 69.8 M | |
| Total Cashflows From Investing Activities | -622 K |
Evelo |
Evelo Biosciences Relative Risk vs. Return Landscape
If you would invest 823.00 in Evelo Biosciences on August 24, 2024 and sell it today you would earn a total of 0.00 from holding Evelo Biosciences or generate 0.0% return on investment over 90 days. Evelo Biosciences is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Evelo, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Evelo Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evelo Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Evelo Biosciences, and traders can use it to determine the average amount a Evelo Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| EVLO |
Based on monthly moving average Evelo Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Evelo Biosciences by adding Evelo Biosciences to a well-diversified portfolio.
Evelo Biosciences Fundamentals Growth
Evelo Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Evelo Biosciences, and Evelo Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Evelo Pink Sheet performance.
| Return On Equity | -62.33 | ||||
| Return On Asset | -0.83 | ||||
| Current Valuation | 23.69 M | ||||
| Shares Outstanding | 18.93 M | ||||
| Price To Earning | (4.19) X | ||||
| Price To Book | 3.51 X | ||||
| EBITDA | (108.41 M) | ||||
| Cash And Equivalents | 92.01 M | ||||
| Cash Per Share | 0.85 X | ||||
| Total Debt | 51.14 M | ||||
| Debt To Equity | 1.55 % | ||||
| Book Value Per Share | (1.42) X | ||||
| Cash Flow From Operations | (101.23 M) | ||||
| Earnings Per Share | (15.64) X | ||||
| Total Asset | 64.44 M | ||||
| Retained Earnings | (529.22 M) | ||||
| Current Asset | 49.29 M | ||||
| Current Liabilities | 4.32 M | ||||
About Evelo Biosciences Performance
By examining Evelo Biosciences' fundamental ratios, stakeholders can obtain critical insights into Evelo Biosciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Evelo Biosciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Evelo Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 122 people.Things to note about Evelo Biosciences performance evaluation
Checking the ongoing alerts about Evelo Biosciences for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Evelo Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Evelo Biosciences is not yet fully synchronised with the market data | |
| Evelo Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (114.53 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Evelo Biosciences currently holds about 92.01 M in cash with (101.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.85. | |
| Over 83.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Evelo Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Evelo Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Evelo Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Evelo Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Evelo Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Evelo Biosciences' pink sheet. These opinions can provide insight into Evelo Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Evelo Pink Sheet
If you are still planning to invest in Evelo Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evelo Biosciences' history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |